CL-197

• UNSPSC Description:

  CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI). CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases[1]. CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• Target Antigen:

  HIV Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/cl-197.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@H]1[C@H](F)[C@H](N2C=NC3=C(N)N=C(F)N=C32)O[C@@]1(CO)C#C

• Molecular Weight:

  311.24

• References & Citations:

  [1]Hou J, et al. 4'-Ethynyl-2'-deoxy-2'-β-fluoro-2-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection. J Med Chem. 2023 Aug 24;66(16):11282-11293.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 1

• CAS Number:

  1030595-07-3